GlycoMark Updates for Healthcare Professionals Caring for Patients with Diabetes
DIABETES MANAGEMENT Issue 14 - January 2019
A New Year Message to Clinicians Managing Patients with Diabetes:
Interview with a Registered Dietitian and Certified Diabetes Educator
Dear GlycoMark Subscriber,

For patients with diabetes, the holidays were likely filled with tempting sweets and opportunities for heavy feasting. The new year is a perfect time to assess glycemic control and help patients get on a healthy new year course.

Surprisingly, up to 40% of patients with a “good” A1C experience significant postprandial hyperglycemia and glycemic variability.1,2

GlycoMark would like to emphasize the importance of close management of patients with diabetes, throughout the year.
We recently asked Denise Surman, a Registered Dietitian (RD) and Certified Diabetes Educator (CDE) from GlycoMark, for her perspectives on four questions about managing patients with diabetes after the holidays.
Which patients would you want to more closely assess for glycemic control?
Because of the overwhelming holiday temptations, I encourage clinicians to be vigilant in patients with diabetes that may not be well controlled.  To know which patients need closer management, you need a closer assessment of glycemic control. Having a GlycoMark Test result on patients where control is questionable is important for the glycemic assessment:
  • Not regularly checking blood sugars
  • Poor diet
  • Poor compliance with treatment or lifestyle changes
  • Concerned about chronic complications
  • Experiencing acute symptoms, polyphagia, polydipsia, and polyuria
  • No-shows for scheduled appointments
  • Depressed
Read the Full Interview
How to Order the GlycoMark Test:
The GlyoMark test can be added to a patient lab workup when ordered through various national and regional laboratories, or is available as a test kit for use on most automated chemistry instruments. The GlycoMark Test is reimbursed by most federal, state and private payors (CPT Code 84378). Click Here for more information!
Denise Surman, RD, CDE is a paid employee of GlycoMark, Inc. For additional clinical perspectives, please visit our website for newsletters, videos, and clinical tools. If you would like to schedule a call with Clinical Affairs, please Contact Us.

1Erlinger TP, Branca FL. Diabetes Care. 2001 Oct;24(10):1734-8.
2Bonora E, et al. Diabetologia. 2006 May;49(5):846-54.

The Mark newsletter is distributed to healthcare professionals that treat and manage patients with diabetes, and contains the latest updates and important references for the GlycoMark test. This is a complimentary publication provided through the generous support of GlycoMark, Inc

The information contained herein is not medical, diagnostic or treatment advice for any particular patient. Physicians should use their clinical judgment and experience when deciding how to diagnose and treat patients and in the use of the GlycoMark test in the treatment of the patient. Please refer to the GlycoMark product insert for more information.

The GlycoMark test is FDA cleared for professional use to provide quantitative measurement of 1,5-anhydroglucitol (1,5-AG) in serum or plasma. The GlycoMark test is intended for intermediate-term monitoring of glycemic control in patients with diabetes. It is not intended to be used to diagnose disease or identify patients that will experience complications of diabetes or the likelihood of experiencing complications.

The information above contains general reimbursement information only and is not legal advice, nor is it advice about how to code, complete, or submit any claim for payment. Providers have the ultimate responsibility for all aspects of coding and billing.

GlycoMark, Inc. is the exclusive licensee of the GlycoMark test, trademark and logo. All other trademarks cited herein are the property of their respective owners. © 2018 GlycoMark, Inc. All Rights Reserved. M-75-1B
805 Third Avenue, 17th Floor, New York, NY 10022
1-888-744-0221 - -